Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company's audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing nov

3 - Silexion Therapeutics Corp (0002022416) (Issuer)

SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced positive data from orthotopic pancreatic cancer models demonstrating that subcutaneously administered SIL204 effectively reduces both primary tumor growth and metastatic spread. These findings represent a significant advancement over previously reported data by providing further validation of SIL204's efficacy in the more clinically relevant orthotopic setting, where human pancreatic tumor cells are implanted directly into the pan

Silexion Therapeutics approaches a potential key milestone with upcoming orthotopic pancreatic cancer model data, which, if positive, could validate systemic efficacy against metastatic disease for the first time. Reportedly, Maxim Group maintains a $9 price target and strong buy rating, citing the company's growing clinical trajectory and RNAi platform validation. With a data readout expected this month, this could be a major catalyst for the company, as interest for innovative KRAS-targeting therapies continues to rise PESG Research releases a new market update on Silexion Therapeutics (NASDAQ:SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in o

Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This milestone represents the first systematic evaluation of SIL-204 administered subcutaneously in clinically relevant pancreatic cancer models. The study specifically evaluated two critical aspects of SIL-204's potential therapeutic profile: SIL-204's ability to reduce primary tumor growth when administered systemically in orthotopic p

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company's ordinary shares originally issued in January 2025 having an exercise price of $1.35 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-282932). The gross proceeds to the Company from the exercise of the warr

Silexion Therapeutics reported 50% Tumor Reduction in Breakthrough Preclinical Systemic Administration Data; Maxim Group Analyst recently gave the company a Strong Buy Rating and a $9 Price Target as Company Advances RNAi Platform for KRAS-Driven Cancers Amid Hot Precision Oncology M&A Market and a series of Multi-Billion Dollar Acquisitions in the field PESG Research releases new market update: Silexion Therapeutics (NASDAQ:SLXN)* continues to strengthen its position in the precision oncology landscape with breakthrough preclinical data validating systemic administration of SIL-204, potentially opening new frontiers in treating KRAS-driven cancers. This development comes amid increasing

Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced promising new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings contribute to validating systemic administration as an effective delivery approach, demonstrating significant tumor growth reduction in orthotopic pancreatic cancer models, a platform designed to mimic human cancer progression. This data underscores SIL-204's potential to address one of the most aggressive and challenging cancers, validating its ability to t

KRAS, one of the most mutated oncogenes across cancers, drives aggressive and treatment-resistant tumors. Silexion's latest data highlights SIL-204's ability to enhance first-line therapies, showcasing its potential to transform outcomes in these hard-to-treat cancers. PESG Releases a Market Update - Silexion Therapeutics (NASDAQ:SLXN), a clinical-stage biotech advancing RNA interference (RNAi) therapies for KRAS-driven cancers, has reported compelling new preclinical data for SIL-204, its next-generation siRNA candidate. These findings reaffirm the company's innovative approach to addressing some of the most challenging cancers, including pancreatic cancer, which is marked by KRAS mutati

Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,703,703 of the Company's ordinary shares (or ordinary share equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined public offering price of $1.35 per share (or per ordinary share equivalent) and accompanying warrant. The warrants will have an exercise price of $1.35 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The clo

Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical results demonstrating the synergistic efficacy of its proprietary second-generation siRNA candidate, SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer. The additional preclinical data show that SIL-204 exhibits significant synergistic activity with 5-fluorouracil and irinotecan—two main components commonly used in pancreatic cancer treatments—when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, t

Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it will be presenting a poster at the 2025 ASCO Gastrointestinal (GI) Cancers Symposium taking place January 23-25, 2025, in San Francisco, California. The 2025 ASCO Gastrointestinal Cancers Symposium is a specialized meeting designed to highlight the latest science in GI cancers and other information oncologists of all subspecialties need to know now, in order to provide the highest quality of care to patients. Silexion's abstract will be published on the ASCO Gastro

GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-9 reverse share split of its ordinary shares. The reverse share split will become effective after market close on November 27, 2024, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Global Market at market open on November 29, 2024, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every nine ordinary shares of